Delving into the Latest Updates on 68Ga-BNOTA-PRGD2 with Synapse

Overview

Basic Info

Drug Type

Peptide Conjugate Radionuclide, Diagnostic radiopharmaceuticals

Synonyms-

Target

αvβ3

Mechanism

αvβ3 antagonists(Integrin alpha-V/beta-3 antagonists), PET imaging(Positron-emission tomography enhancers)

Therapeutic Areas

Respiratory DiseasesOther DiseasesNeoplasms+ [4]

Active Indication-

Inactive Indication

Acute Lung InjuryCoronary Artery DiseaseGlioma+ [5]

Originator Organization

Beijing Xiehe Bioengineering United Company

Active Organization-

Inactive Organization

Peking Union Medical College HospitalBeijing Xiehe Bioengineering United Company

Drug Highest PhasePendingPhase 1

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Sequence Code 1507071

This is an open-label brain PET/CT (positron emission tomography/computed tomography) study to investigate the diagnostic performance and evaluation efficacy of 68Ga-BNOTA-PRGD2 in glioma patients. A single dose of nearly 111 MBq 68Ga-BNOTA-PRGD2 (≤40 µg BNOTA-PRGD2) will be intravenously injected into patients in suspicion of glioma. Visual and semiquantitative method will be used to assess the PET/CT images. Brain MRI with/without enhancement and 18F-FDG PET/CT will be performed for comparison. The postoperative pathology and integrin αvβ3 and CD34 immunohistochemical stains will also be used for correlation.

Start Date01 Oct 2012

Sponsor / Collaborator

Peking Union Medical College Hospital

[+1]

NCT01542073

/ Unknown statusEarly Phase 1IIT

68Ga-BNOTA-PRGD2 PET/CT in Evaluation of Angiogenesis of Myocardial Infarction and the Comparison With Cardiac Perfusion and Metabolism

This is an open-label PET/CT (positron emission tomography/computed tomography) study to investigate the diagnostic performance of 68Ga-BNOTA-PRGD2 in evaluation of myocardial infarction. A single dose of nearly 111 MBq 68Ga-BNOTA-PRGD2 ( ≤ 40 µg BNOTA-PRGD2) will be intravenously injected into myocardial infarction patients. Visual and semiquantitative method will be used to assess the 68Ga-BNOTA-PRGD2 PET/CT cardiac images and compared to the 99mTc-MIBI SPECT myocardial perfusion images and the 18F-FDG metabolism images.

Start Date01 Feb 2012

Sponsor / Collaborator

Peking Union Medical College Hospital

NCT01940926

/ Unknown statusEarly Phase 1IIT

Diagnostic Performance and Evaluation Efficacy of 68Ga-BNOTA-PRGD2 PET/CT in Patients With Rheumatoid Arthritis

This is an open-label positron emission tomography/computed tomography ( PET/CT) study to investigate the diagnostic performance and evaluation efficacy of 68Ga-BNOTA-PRGD2 in rheumatoid arthritis (RA) patients. A single dose of nearly 111 MBq 68Ga-BNOTA-PRGD2 (≤ 40 µg BNOTA-PRGD2) will be intravenously injected into patients with RA. Visual and semiquantitative method will be used to assess the PET/CT images. Whole body 18F-FDG PET/CT will be performed for comparison.

Start Date01 Feb 2012

Sponsor / Collaborator

Peking Union Medical College Hospital

100 Clinical Results associated with 68Ga-BNOTA-PRGD2

Login to view more data

100 Translational Medicine associated with 68Ga-BNOTA-PRGD2

Login to view more data

100 Patents (Medical) associated with 68Ga-BNOTA-PRGD2

Login to view more data

100 Deals associated with 68Ga-BNOTA-PRGD2

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Glioma	Phase 1	CN	Peking Union Medical College Hospital	01 Oct 2012
Coronary Artery Disease	Phase 1	CN	Peking Union Medical College Hospital	01 Feb 2012
Myocardial Infarction	Phase 1	CN	Peking Union Medical College Hospital	01 Feb 2012
Rheumatoid Arthritis	Phase 1	CN	Peking Union Medical College Hospital	01 Feb 2012
Stroke	Phase 1	CN	Peking Union Medical College Hospital	01 Feb 2012
Lung Cancer	Phase 1	CN	Peking Union Medical College Hospital	01 Dec 2011
Acute Lung Injury	Phase 1	-	Beijing Xiehe Bioengineering United Company	-
Pulmonary Fibrosis	Phase 1	-	Beijing Xiehe Bioengineering United Company	-